| Document |
Document Title |
|
WO/2024/027013A1 |
A crystal form II of elobixibat. The X-ray powder diffraction pattern of the crystal form II has specific peaks at 2θ values 9.4±0.2° and 7.8±0.2° and has one or more of following characteristic peaks: 3.9±0.2°, 11.7±0.2°, 16.1Â...
|
|
WO/2024/008766A1 |
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (...
|
|
WO/2023/240135A2 |
Provided are new bifunctional chelators for use in the manufacture of radiolabeled targeting agents for therapeutic or diagnostic use. Also provided are conjugates of the new bifunctional chelators with various cancer antigen targeting a...
|
|
WO/2023/164183A1 |
The present disclosure provides, in part, benzothia(dia)zepine compounds, and pharmaceutical compositions thereof, and methods of treating Hepatitis B (HBV) and Hepatitis D (HDV) infections.
|
|
WO/2023/119210A1 |
The present invention relates to a compound as an RIPK1 inhibitor, a stereoisomer thereof, a tautomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and a pharmaceutical composition comprisi...
|
|
WO/2023/091524A1 |
The present disclosure provides methods of treating catecholaminergic polymorphic ventricular tachycardia, comprising administering a pharmaceutical composition comprising, in a unit dosage form, a therapeutically-effective amount of 4-[...
|
|
WO/2023/070091A1 |
A method of treating essential tremor (ET) includes administering a calcium channel stabilizer to a patient in need thereof. The calcium channel stabilizer enhances or restores the binding of leaky RyR1 with calstabin-1 in brain cells, a...
|
|
WO/2023/030295A1 |
A compound having a USP1 inhibitory activity or function and a pharmaceutically acceptable salt thereof. The compound has the structure of formula (I), and have substituents and structural features described in the present invention. Als...
|
|
WO/2022/257288A1 |
The present invention belongs to the field of drug synthesis, and discloses a method for synthesizing diltiazem hydrochloride and the use thereof. The method for synthesizing diltiazem hydrochloride provided by the present invention comp...
|
|
WO/2022/253997A1 |
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter(ASBT) and/or liver bile acid transport (L...
|
|
WO/2022/228413A1 |
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...
|
|
WO/2022/222856A1 |
A benzo-condensed ring compound of formula (I), a pharmaceutical composition comprising same, a preparation method therefor and a use thereof as an HDAC6 inhibitor.
|
|
WO/2022/150603A1 |
The present disclosure relates to crystalline forms of the compound 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]
benzoic acid hemifumarate, pharmaceutical compositions comprising these compounds and uses thereof to treat ...
|
|
WO/2022/136335A1 |
Disclosed are crystalline and amorphous forms of linerixibat and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof. Also disclosed is solubility and diss...
|
|
WO/2022/117778A1 |
The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid ...
|
|
WO/2022/108945A1 |
The present disclosure relates to 1,4-benzothiazepine derivatives and use thereof to treat conditions associated with ryanodine receptors that regulate calcium channel functioning in cells.
|
|
WO/2022/074589A1 |
The present disclosure provides a compound having the structure: Formula (I) or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and C...
|
|
WO/2022/074587A1 |
The present disclosure relates to a compound having the structure: Formula (I) or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and...
|
|
WO/2022/074588A1 |
The present disclosure provides a compound having the structure: Formula (I) wherein R1 is –H or –(alkyl); R2 is -(alkyl)-CO2H or -(alkyl)-CO2-(alkyl); R3 is –H or –(alkyl); and X is -Br or -I, or a pharmaceutically acceptable sa...
|
|
WO/2022/029101A1 |
The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid ...
|
|
WO/2021/243461A1 |
Disclosed is a method of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication thereof, and/or altering the diet of an individual comprising administering DMT, LSD, LSA, or an analog thereof.
|
|
WO/2021/226168A1 |
Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound F that can be used to prepare them where the variable PG is as defined herein. In particular, provided herein are processes for synthesizi...
|
|
WO/2021/208945A1 |
Disclosed are a benzonitric heterocyclic compound, a preparation method therefor and the use thereof. Provided in the present invention is a benzonitric heterocyclic compound represented by formula I, or a pharmaceutically acceptable sal...
|
|
WO/2021/110887A1 |
The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. Th...
|
|
WO/2021/110883A1 |
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (...
|
|
WO/2021/110884A1 |
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (...
|
|
WO/2021/110886A1 |
The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid ...
|
|
WO/2021/049311A1 |
Provided is a method for producing a 1,5-benzothiazepin compound, the method being suitable for large, industrial scale production in which less solvent is used, intermediates are not repeatedly purified, and a high-yield of high-purity ...
|
|
WO/2020/161216A1 |
The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium- dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. T...
|
|
WO/2020/145250A1 |
[Problem] To provide a compound having a 15-PGDH inhibitory effect. [Solution] A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.
|
|
WO/2020/027927A1 |
Dosage forms, formulations, and methods for administering sublingual diltiazem and its use in the treatment of supraventricular arrhythmias, hypertension, coronary artery disease and Raynaud's phenomenon are disclosed.
|
|
WO/2019/234077A1 |
The invention relates to1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (L...
|
|
WO/2019/185882A1 |
The invention provides compounds of the formula (1) or salts or tautomers thereof; wherein: Q is SO or SO2; n is 1 or 2; R1 is selected from hydrogen and a non-aromatic C1-6 hydrocarbon group; R2 and R3 are independently selected from hy...
|
|
WO/2019/173761A1 |
Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as "c-Abl"). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site an...
|
|
WO/2019/172834A1 |
The present invention relates to a process for the preparation of certain 1,5-benzothiazepine compounds, and in particular toa process for the preparation of elobixibat. The process can be carried out under mild and safe conditions and m...
|
|
WO/2019/082910A1 |
Provided are: a V2 receptor antagonist which has high water solubility and which is particularly suitable for injections; and a medicine containing the V2 receptor antagonist or the like. The present invention is a compound represented b...
|
|
WO/2019/039290A1 |
Provided are: an actinic ray-sensitive or radiation-sensitive resin composition that has excellent resolution, exposure latitude, and pattern shape properties; and a resist film, a pattern-forming method, a method for producing an electr...
|
|
WO/2018/170275A1 |
The present invention provides a compound having the structure:, or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with a pain, a depressive disorder, a mood disorder, an anxiety disorde...
|
|
WO/2018/122606A1 |
Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6- methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula (I).
|
|
WO/2018/002827A1 |
Methods for the preparation of the following compound are disclosed. The compound can be incorporated into pharmaceutical formulations, including tablets and such tablets can be used for treating cholestatic liver diseases.
|
|
WO/2017/112988A1 |
The present invention describes molecules with a hybrid nucleus based on tetrahydroacridine and tianeptine nuclei separated by methyl spacer chains via a coupling reaction, a pharmaceutical composition comprising these molecules, a metho...
|
|
WO/2017/109178A1 |
A subject of the present invention is the use of a compound having the general formula (I): (I) wherein V, W, X4, X5, X6, X7, X'4, X'5, X'6, X'7, Y, Y', R3, R'3, R4 and R'4 are as defined in any one of claims 1 to 11, for the detection, ...
|
|
WO/2017/055834A1 |
Tricyclic dibenzothiazepine compounds for use in the treatment of CDKL5 disorder. Specifically, a compound of Formula I, or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solv...
|
|
WO/2017/049158A1 |
The present invention provides a compound having the structure of the instant invention or a pharmaceutically acceptable salt or ester thereof, methods of preparing the same, and methods of treating a subject with compounds of the instan...
|
|
WO/2017/048954A1 |
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a pat...
|
|
WO/2017/044571A1 |
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus : The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP...
|
|
WO/2016/151011A1 |
2-homopiperazine-1-yl-4H-l, 3 -bensothiazine-4-one derivatives of formula (I) are provided. They are useful in the treatment of bacterial infections, in particular tuberculosis, buruli ulcer and leprosy. A process for the preparation of ...
|
|
WO/2016/143650A1 |
Provided is a compound that exhibits an excellent controlling effect against harmful arthropods. A 3-aminooxalylaminobenzamide compound represented by formula (1) has an excellent controlling effect against harmful arthropods.
|
|
WO/2016/139181A1 |
The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions com...
|
|
WO/2016/109596A1 |
Disclosed are novel calcium modulators having formula I: or a pharmaceutically acceptable salt, and including deuterated forms thereof, wherein: Z1, Z2, Z3, Z4 Z5, R1, R1', R2, R3, R3' R4, and R4', are as defined throughout the specifica...
|
